Investigating levodopa-induced dyskinesias in the Parkinsonian primate

Annals of Neurology

Volumn 47, Issue 4 SUPPL. 1, 2000, Pages

  Langston, J William ^a   Quik, Maryka ^a   Petzinger, Giselle ^a   Jakowec, Michael ^a   Di Monte, Donato A ^a  

^a PARKINSON S INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; LEVODOPA; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; DOPAMINE BRAIN LEVEL; DRUG INDUCED DISEASE; DYSKINESIA; HYPOTHESIS; MONKEY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; RATING SCALE; RELIABILITY;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; LEVODOPA; PARKINSON DISEASE, SECONDARY; PRIMATES;

EID: 0034070321     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (107)

1. Chase TN, Mouradian MM, Engber TM. Motor response complications and the function of striatal efferent systems. Neurology 1993;43:S23-S26
2. Chase TN, Engher TM, Mouradian MM. Striatal DA receptor system changes and motor response complications in L-dopa-treated patients with advanced disease. Adv Neurol 1993;60: 181-185
3. Peppe A, Dambrosia JM, Chase TN. Risk factor for motor response complications in L-dopa-treated Parkinsonian patients. Adv Neurol 1993;60:698-702
4. Mouradian MM, Juncos JL, Fabbrini G, Chase TN. Motor fluctuations in Parkinson's disease: pathogenic and therapeutic studies. Ann Neurol 1987;22:475-479
5. Mouradian MM, Juncos JL, Fabbrini G, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Ann Neurol 1988;24:372-378
6. Mouradian MM, Heuser IJ, Baronti F, et al. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989;25:523-526
7. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987;2:73-91
8. Marconi R, Lefebvre-Caparros D, Bonnet A-M, et al. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 1994;9:2-12
9. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease: clinical aspects. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworth, 1981:96-122
10. Nutt JG. Dyskinesia induced hy levodopa and dopamine agonists in patients with Parkinson's disease. In: Lang AE, Weiner WJ, eds. Drug-induced movement disorders. Mount Kisko: Futura Publisher, 1992:281-314
11. Blanchet PJ, Calon F, Martel JC, et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 1995;272: 854-859
12. A receptors in the striatopallidal complex. Brain Res 1995;680:43-52
13. Goulet M, Grondin R, Blanchet PJ, et al. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys. Brain Res 1996;719:129-137
14. Quinn NP. Modern management of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;50:93-95
15. Marsden CD. Parkinson's disease. Lancet 1990;335:948-952
16. Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman A, eds. The scientific basis for the treatment of Parkinson's disease. Carnforth: Parthenon, 1992:89-112
17. Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 1993;43:1698-1703
18. Poewe W. Clinical and pathophysiologic aspects of late levodopa failure. Neurology 1993;43(12 Suppl 6):S28-S30
19. Tanner CM, Melamed E, Lees AJ. Managing motor fluctuations, dyskinesias, and other adverse effects in Parkinson's disease. Neurology 1994;44:S12-S16
20. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutaminergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv Neurol 1996;69:497-501
21. Chesselet MF, Delfs JM. Basal ganglia and movement disorders: an update. Trends Neurosci 1996;19:417-422
22. Albin RL. The pathophysiology of chorea/ballism and parkinsonism. Parkinsonism Related Disord 1995;1:3-11
23. Blunt SB, Jenner P, Marsden CD. Motor function, graft survival and gliosis in rats with 6-OHDA lesions and fetal ventral mesencephalic grafts chronically treated with L-dopa and carbidopa. Exp Brain Res 1992;88:326-340
24. Gaudin DP, Rioux L, Bédard PJ. Fetal dopamine neuron transplants prevent behavioral super sensitivity induced by repeated administration of L-dopa in the rat. Brain Res 1990;506:166-168
25. Abercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxy-dopamine-treated rats. Brain Res 1990;5251:36-44
26. Zigmond MJ, Abercrombie E, Berger TW, et al. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 1990;13:290-296
27. 3H]flunitrazepam. Neuroscience 1993;57:673-681
28. Sakai K, Gash DM. Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat. Brain Res 1994; 633:144-150
29. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 DA receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-1432
30. Gerfen CR, Keefe KA, Gauda EB. D1 and D2 dopamine receptor function in the striatum: coactivation of D1- and D2-dopamine receptors on separate populations of neurons results in potentiated immediate early gene response in D1-containing neurons. J Neurosci 1995;15:8167-8176
31. Joyce JN, Marshall JF, Bankiewicz KS, et al. Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of MPTP is associated with regional ipsilateral changes in striatal D-2 receptor density. Brain Res 1986;382:360-364
32. Engber TM, Susel Z, Kuo S, Chase TN. Chronic levodopa replacement therapy alters basal and dopamine agonist stimulated cerebral glucose utilizarion. J Neurosci 1990;10:3889-3895
33. Engber TM, Susel Z, Kuo S, et al. Levodopa replacement therapy alters enzyme activity in striatum output and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 1991;552:113-118
34. Cenci MA, Campbell K, Wiktorin K, Björklund A. Striatal c-fos induction by cocaine or apomorphine occurs preferentially in output neurons projecting to the substantia nigra. Eur J Neurosci 1992;4:376-380
35. Cenci MA, Campbell K, Björklund A. Neuropeptide-mRNA expression in the 6-hydroxydopamine lesioned rat striatum reinnervated by fetal dopaminergic transplants: differential effects of the grafts on preenkephalin-, preprotachykinin-, and pronorphin-mRNA levels. Neuroscience 1993;57:132-147
36. Bédard PJ, Di-Paolo T, Falardeau P, Boucher R. Chronic treatment with L-dopa, but not bromocriptine induces dyskinesias in MPTP-parkinsonian monkeys. Correlation with [(3)H]spiperone binding. Brain Res 1986;379:294-299
37. Bédard PJ, Gomez-Mancilla B, Blancette P, et al. Levodopa-induced dyskinesia; facts and fancy. What does the MPTP monkey model tell us? Can J Neurol Sci 1992;19(Suppl):134-137
38. Bédard PJ, Gomez-Mancilla B, Blancette P, et al. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys. Adv Neurol 1993;60:113-118
39. Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD. Differential effects of D-1 and D-2 antagonists in MPTP-treated primates. Implications for Parkinson's disease. Neurology 1990;40:927-933
40. Boyce S, Clarke CE, Luquin R, et al. Induction of chorea and dystonia in parkinsonian primates. Mov Disord 1990;5:3-7
41. Boyce S, Rupniak NMJ, Steventon M, Iversen SD. CCK-8S inhibits L-dopa-induced dyskinesias in parkinsonian squirrel monkeys. Neurology 1990;40:717-718
42. Boyce S, Rupniak NMJ, Steventon M, Iversen SD. Characterization of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys. Psychopharmacology 1990;102:21-27
43. Boyce S, Rupniak NMJ, Sreventon M, Iversen SD. Nigrostriatal damage is required for induction or dyskinesias by L-dopa in squirrel monkeys. Clin Neuropharmacol 1990;13:448-458
44. Crossman AR. Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience 1987;21:1-40
45. Gagnon C, Bédard PJ, Di-Paolo T. Effects of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists. Eur J Pharmacol 1990;178:115-120
46. Gomez-Mancilla B, Bédard PJ. Effect of D-1 and D-2 agonists and antagonists on dyskinesia produced by L-dopa in MPTP-treated monkeys. J Pharmacol Exp Ther 1991;259:409-413
47. Graham WC, Sambrook MA, Crossman AR. Differential effect of chronic dopa treatment on DA D-1 and D-2 receptors in monkey brain in MPTP-induced parkinsonism. Brain Res 1992; 602:290-303
48. Luquin MR, Laguna J, Obeso JA. Selective D-2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann Neurol 1992;31:551-554
49. Page DR. Use of thalamotomy in treatment of L-dopa-induced dyskinesias. Acta Neuroschir 1992;114:77-117
50. Page RD, Sambrook MA, Crossman AR. Thalamotomy for alleviation of levodopa-induced dyskinesia: experimental studies in the MPTP-treated parkinsonian monkey. Neuroscience 1993;55: 147-165
51. Rupniak NMJ, Boyce S, Steventon MJ, et al. Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys. Ann Neurol 1992;32:103-105
52. Schneider JS. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharm Biochem Behav 1989;34:193-196
53. Tye SJ, Rupniak NMJ, Naruse T, et al. NB-355: a novel pro-drug for L-dopa with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys. Clin Neuropharmacol 1989;12:393-403
54. Langston JW, Ballard P. Parkinsonism induced by MPTP: implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sci 1984;11:160-165
55. Gnanalingham KK, Smith LA, Hunter AJ, Jenner P, Marsden CD. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study. Synapse 1993;14:184-194
56. Watts VJ, Lawler CP, Gilmore JH, et al. Dopamine D1 receptors: efficacy of full (dihydrexidin) vs. partial (SKF38393) agonists in primates vs. rodents. Eur J Pharmacol 1993;28:165-172
57. Hurley MJ, Jolkkonen J, Stubbs CM, et al. Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment. Brain Res 1996;709:259-264
58. Morissette M, Goulet M, Grondin R, et al. Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur J Neurosci 1998;10:2565-2573
59. Ueda H, Sato K, Okumura F, et al. Supersensitivity of neurochemical response of L-dopa and DA receptor agonists in striatum of Parkinson's disease model rats. Biomed Pharmacol 1995;49: 169-177
60. Ceula C, Schatz CR, Mesulam MM. Differential localization of NADPH-diaphorase and calbindin-D28k within the cholinergic neurons of the basal forebrain, striatum, and brainstem in the rat, monkey, baboon, and human. Neuroscience 1993;54:461-476
61. Mones RJ. Experimental dyskinesias in normal rhesus monkey. Adv Neurol 1973;1:665-669
62. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990;13:266-271
63. Alexander GM, Brainard DL, Gordon SW, et al. Dopamine receptor changes in untreated and (+)PHNO-treated MPTP primates. Brain Res 1991;547:181-189
64. Di Monte DA, Petzinger GM, McCormack AE, Janson AM, Quik M, Langston JW. Nigrostriatal degeneration, parkinsonism and dyskinesia in the suirrel monkey [abstract]. Neurosci 1999;25:1339
65. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880
66. Civelli O, Bunzow JR, Grandy DK. Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol 1993;32: 281-307
67. Seeman P, van Tol HHM. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994;15:264-269
68. Sokoloff P, Schwartz JC. Novel dopamine receptors half a decade later. Trends Pharmacol Sci 1995;16:270-275
69. 3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 1997;49:231-252
70. Grondin R, Goulet M, Bédard PJ, Di Paolo T. Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naïve primates. Brain Res 1996;753:298-306
71. Morissette M, Goulet M, Calon F, et al. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine. Mol Pharmacol 1996;50:1073-1079
72. 2 receptor expression: in situ hybridization histochemical analysis. Neuroscience 1997;79: 497-507
73. Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998;339:1105-1111
74. Daly SA, Waddington JL. Behavioral effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other D-2-like agonists. Neuropharmacology 1993;32:509-510
75. Waters N, Svensson K, Haadsma SR, et al. The dopamine D-3 receptor: postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm 1993;94:11-19
76. Meller E, Bohmaker K, Goldstein M, Basham DA. Evidence that striatal synthesis-inhibiting autoreceptors are dopamine D3 receptors. Eur J Pharmacol 1993;249:R5-R6
77. Levesque D, Martres MP, Diaz J, et al. A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc Natl Acad Sci USA 1995;92:1719-1723
78. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci 1994;17:31-108
79. Standeart DG, Testa CM, Young AB, Penney JB. Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J Comp Neurol 1994;343:1-16
80. 3H]kainate. Brain Res 1994;658:209-218
81. Bernard V, Somogyi P, Bolam JP. Cellular, subcellular, and subsynaptic distribution of AMPA-type glutamate receptor subunits in the neostriatum or the rat. J Neurosci 1997;17:819-833
82. Ong WY, He Y, Garey LJ. Localization of glutamate receptors in the substantial nigra pars compacta of the monkey. J Hirnforsch 1997;38:291-298
83. Jakowec MW, Jackson-Lewis V, Chen X, et al. The postnatal development of AMPA receptor subunits in the basal ganglia of the rat. Dev Neurosci 1998;20:19-33
84. Clarke NP, Bolam JP. Distribution of glutamate receptor subunits at neurochemically characterized synapses in the entopeduncular nucleus and subthalamic nucleus of the rat. J Comp Neurol 1998;397:403-420
85. Loschmann PA, Wullner U, Heneka MT, et al. Differential interaction of competitive NMDA and AMPA antagonists with selective dopaminc D-1 and D-2 agonists in a rat model of Parkinson's disease. Synapse 1997;26:381-391
86. Smith Y, Charara A, Parent A. Synaptic innervation of midbrain dopaminergic neurons by glutamate-enriched terminals in the squirrel monkey. J Comp Neurol 1996;364:231-253
87. Abarca JK, Gysling RH, Bustos G. Changes in extracellular levels of glutamate and aspartate in rat substantia nigra induced by dopamine receptor ligands: in vivo microdialysis studies. Neurochem Res 1995;20:159-169
88. Christofferson CL, Meltzer LT. Evidence for N-methyl-D-aspartate and AMPA subtypes of the glutamate receptor on substantia nigra dopamine neurons: possible preferential role for N-methyl-D-aspartate receptors. Neuroscience 1995;67:373-381
89. Bezard E, Boraud T, Bioulac B, Gross CE. Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism. Neuroscience 1997;81:399-404
90. Graham WC, Robertson RG, Sambrook MA, Crossman AR. Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism. Life Sci 1990;47:PL91-PL97
91. Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 1994;5:2586-2588
92. Papa SM, Boldry RC, Engber TM, et al. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 1995;701:13-18
93. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 1996;39:574-578
94. Klockgether T, Turski L, Honore T, et al. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 1991;30: 717-723
95. Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 1998;13:798-802
96. Verhagen Metman L, del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-1326
97. Verhagen Metman L, Blanchet PJ, van den Muckhof P, et al. A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord 1998;13:414-417
98. Crossman AR, Peggs D, Boyce S, et al. Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey. Neuropharmacology 1989;28:1271-1273
99. Fredriksson A, Gentsch C, Archer T. Synergistic interactions between NMDA-antagonists and L-dopa on activity in MPTP-treated mice. J Neural Transm Gen Sect 1994;97:197-209
100. Dall'Olio R, Rimondini R, Gandolfi O. The competitive NMDA antagonists CGP 43487 and APV potentiate dopaminergic function. Psychopharmacology 1993;118:310-315
101. Nakanishi N, Schneider NA, Axel R. A family of glutamate receptor genes: evidence for the formation of heteromultimeric receptors with distinct channel properties. Neuron 1990;5:569-581
102. Ulas J, Cotman CW. Dopaminergic denervation of striatum results in elevated expression of NR2A subunit. Neuroreport 1996;7:1789-1793
103. Oh JD, Russell D, Vaughan CL, Chase TN. Enhanced tyrosine phosphorylation of striaral NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Res 1998;813:150-159
104. Kotter R. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog Neurobiol 1994;44: 163-196
105. Starr MS. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 1995;19: 264-293
106. Lange KW, Kornhuber J, Riederer P. Dopamine/glutamate interactions in Parkinson's disease. Neurosci Biobehav Rev 1997;21: 393-400
107. Andres ME, Gysling K, Bustos G. Differential regulation of dopamine release by N-methyl-D-aspartate receptors in rat striatum after partial and extreme lesions of the nigra-striatal pathway. Brain Res 1998;797:255-266